We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Olorofim

News List

F2G Receives Second FDA Breakthrough Therapy Designation for Olorofim americanpharmaceuticalreview
October 29, 2020
F2G announced the US Food and Drug Administration (FDA) has granted an additional Breakthrough Therapy Designation to its lead first-in-class candidate, olorofim, for the indication of “Treatment of Central Nervous System (CNS) coccidioidomycosis ...
F2G Receives Orphan Drug Designation for Olorofim americanpharmaceuticalreview
March 10, 2020
F2G announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead first-in-class candidate, olorofim (formerly F901318) for treatment of invasive aspergillosis ...